Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - May 2017

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Liraglutide (Saxenda®) has been rejected for use as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index of:

  • ≥30kg/m2 (obese)
  • ≥27kg/m2 and <30kg/m2 (overweight) with at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea

The manufacturer failed to make a submission.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - May 2017' on Email Share 'SMC Update - May 2017' on Delicious Share 'SMC Update - May 2017' on Digg Share 'SMC Update - May 2017' on Facebook Share 'SMC Update - May 2017' on Google+ Share 'SMC Update - May 2017' on reddit Share 'SMC Update - May 2017' on StumbleUpon Share 'SMC Update - May 2017' on Twitter

atomic-wealth

No Comments to “SMC Update - May 2017”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,413 spam comments.

atomic-wealth
fond-illness
summer